Quarterly ResultJul 23, 2026, 06:51 AM
Quest Diagnostics Q2 Revenue $3.04B, Adj. EPS $3.12; Raises FY26 Guidance
AI Summary
Quest Diagnostics reported strong financial results for the second quarter ended June 30, 2026, with revenues increasing 10.2% to $3.04 billion and adjusted diluted EPS growing 19.1% to $3.12. Following this performance, the company raised its full-year 2026 guidance, now expecting revenues between $11.95 billion and $12.05 billion, and adjusted diluted EPS between $11.05 and $11.25. Key highlights include robust organic revenue growth, advancements in Co-Lab Solutions, and double-digit growth in Advanced Diagnostics.
Key Highlights
- Q2 2026 Net revenues reached $3.04 billion, a 10.2% increase from 2025.
- Q2 2026 Reported diluted EPS was $2.84, up 15.0% from 2025.
- Q2 2026 Adjusted diluted EPS was $3.12, up 19.1% compared to 2025.
- Full-year 2026 revenue guidance raised to $11.95 billion - $12.05 billion.
- Full-year 2026 adjusted diluted EPS guidance raised to $11.05 - $11.25.
- Organic revenue growth for Q2 2026 was 10.0%.
- Cash provided by operations for Q2 2026 was $597 million, up 9.7%.
- Repurchased 0.5 million shares for $100 million in Q2 2026.
Price Impact
More from DGX